Usefulness of 5 Minutes 123I-mIBG Scan in Parkinson’s Disease and Heart Failure

Author(s): Viviana Frantellizzi*, Maria Ricci, Alessio Farcomeni, Mariano Pontico, Arianna Pani, Giuseppe De Vincentis

Journal Name: Current Radiopharmaceuticals

Volume 13 , Issue 2 , 2020

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The use of 123I-mIBG has been approved for decades for Parkinson’s disease (PD) diagnosis and as a predictor of mortality and potentially fatal events in patients with Heart Failure (HF). The standardized technique includes an early acquisition (15 minutes from injection), and a late acquisition (240 minutes). Early images mainly represent interstitial uptake, whereas delayed images represent actual neuronal uptake, however, it is reasonable to affirm that different pathological situations, such as PD and HF, imply a different meaning for early and late imaging.

Objective: This prospective study aims to investigate the clinical usefulness of an immediate planar 123I-mIBG image acquisition (5 minutes) both in patients with PD and in patients with HF.

Methods: 115 patients referred to 123I-mIBG cardiac imaging in Nuclear Medicine Center have been enrolled (60 patients with PD, absence of diabetes and/or cardiologic pathology, Hoehn e Yahr classification ≤ 1.5; 55 patients with cardiomyopathy, diagnosis of HF, NYHA class I–III). 123I-mIBG planar anterior thoracic acquisitions were performed after 5 (immediate), 15 (early) and 240 (late) minutes from injection and H/M ratios were calculated.

Results: In PD group H/M mean values resulted in 1.58±0.22 for immediate (5 min), 1.61±0.26 for early (15 min) and 1.59±0.37 for late (240 min) acquisitions. In the HF group, H/M mean values resulted in 1.63±0.24 for immediate (5 min), 1.65±0.22 for early (15 min) and 1.57±0.17 for late (240 min) acquisitions, respectively. H/M values obtained at 5 min and 15 min are provided similar results, with no statistical difference (p = ns) regardless of the pathology examined (PD or HF groups). The statistical analyses validated the diagnostic role of immediate acquisition (5 min) and early acquisition (15 min) in PD group as compared to the standardized late acquisition (240 min). On the contrary, in HF group, immediate and early acquisition, as compared to late acquisition (240 min), is not validated as a major cardiac events predictor.

Conclusion: Our results indicate the potential role of immediate (5 min) or early (15 min) acquisition in replacement of standardized 240 minutes acquisition in PD patients, but this result is not confirmed in HF patients, in which the acquisition at 240 min is confirmed as the most affordable timing for image interpretation, emphasizing the different pathophysiology that underlies these two pathologies.

Keywords: 123I-mIBG imaging, Parkinson’s disease, heart failure, cardiac sympathetic activity, acquisition technique, acquisition timing.

[1]
Nakajima, K.; Verschure, D.O.; Okuda, K.; Verberne, H.J. Standardization of 123I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications. Clin. Transl. Imaging, 2017, 5(3), 255-263.
[http://dx.doi.org/10.1007/s40336-017-0230-2] [PMID: 28596948]
[2]
Verberne, H.J. Assessment of cardiac sympathetic innervation with (123)I-mIBG SPECT comes to life: need for standardization! Eur. Heart J. Cardiovasc. Imaging, 2016, 17(4), 391-392.
[http://dx.doi.org/10.1093/ehjci/jev348] [PMID: 26819325]
[3]
Boogers, M.J.; Borleffs, C.J.; Henneman, M.M.; van Bommel, R.J.; van Ramshorst, J.; Boersma, E.; Dibbets-Schneider, P.; Stokkel, M.P.; van der Wall, E.E.; Schalij, M.J.; Bax, J.J. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J. Am. Coll. Cardiol., 2010, 55(24), 2769-2777.
[http://dx.doi.org/10.1016/j.jacc.2009.12.066] [PMID: 20538172]
[4]
Nuvoli, S.; Palumbo, B.; Malaspina, S.; Madeddu, G.; Spanu, A. 123I-ioflupane SPET and 123I-MIBG in the diagnosis of Parkinson’s disease and parkinsonian disorders and in the differential diagnosis between Alzheimer’s and Lewy’s bodies dementias. Hell. J. Nucl. Med., 2018, 21(1), 60-68.
[PMID: 29550847]
[5]
Jacobson, A.F.; Senior, R.; Cerqueira, M.D.; Wong, N.D.; Thomas, G.S.; Lopez, V.A.; Agostini, D.; Weiland, F.; Chandna, H.; Narula, J. ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J. Am. Coll. Cardiol., 2010, 55(20), 2212-2221.
[http://dx.doi.org/10.1016/j.jacc.2010.01.014] [PMID: 20188504]
[6]
Vaccaro, F.; Caccavo, D.; Roumpedaki, E.; De Vincentis, G.; Di Gioia, C.R.; Gallo, P.; Palange, P. Dilated cardiomyopathy due to thrombotic microangiopathy as the only manifestation of antiphospholipid syndrome: a case report. Int. J. Immunopathol. Pharmacol., 2008, 21(1), 237-241.
[http://dx.doi.org/10.1177/039463200802100128] [PMID: 18336752]
[7]
De Vincentis, G.; Frantellizzi, V.; Fedele, F.; Farcomeni, A.; Scarparo, P.; Salvi, N.; Fegatelli, D.A.; Mancone, M.; Verschure, D.O.; Verberne, H.J. Role of cardiac 123I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD. J. Nucl. Cardiol., 2019, 26(4), 1188-1196.
[http://dx.doi.org/10.1007/s12350-018-1258-z] [PMID: 29594915]
[8]
Verberne, H.J.; Brewster, L.M.; Somsen, G.A.; van Eck-Smit, B.L. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur. Heart J., 2008, 29(9), 1147-1159.
[http://dx.doi.org/10.1093/eurheartj/ehn113] [PMID: 18349024]
[9]
Parker, M.W.; Sood, N.; Ahlberg, A.W.; Jacobson, A.F.; Heller, G.V.; Lundbye, J.B. Relationship between quantitative cardiac neuronal imaging with (1)(2)(3)I-meta-iodobenzylguanidine and hospitalization in patients with heart failure. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(9), 1666-1672.
[http://dx.doi.org/10.1007/s00259-014-2819-2] [PMID: 24915891]
[10]
Dimitriu-Leen, A.C.; Gimelli, A.; Al Younis, I.; Veltman, C.E.; Verberne, H.J.; Wolterbeek, R.; Zandbergen-Harlaar, S.; Bax, J.J.; Scholte, A.J.H.A. The impact of acquisition time of planar cardiac (123)I-MIBG imaging on the late heart to mediastinum ratio. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(2), 326-332.
[http://dx.doi.org/10.1007/s00259-015-3220-5] [PMID: 26515715]
[11]
Arbab, A.S.; Koizumi, K.; Takano, H.; Uchiyama, G.; Arai, T.; Mera, K. Parameters of dynamic and static iodine-123-MIBG cardiac imaging. J. Nucl. Med., 1995, 36(6), 962-968.
[PMID: 7769453]
[12]
Nakajo, M.; Shimabukuro, K.; Yoshimura, H.; Yonekura, R.; Nakabeppu, Y.; Tanoue, P.; Shinohara, S. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J. Nucl. Med., 1986, 27(1), 84-89.
[PMID: 3941369]
[13]
Gelb, D.J.; Oliver, E.; Gilman, S. Diagnostic criteria for Parkinson disease. Arch. Neurol., 1999, 56(1), 33-39.
[http://dx.doi.org/10.1001/archneur.56.1.33] [PMID: 9923759]
[14]
Gilman, S.; Wenning, G.K.; Low, P.A.; Brooks, D.J.; Mathias, C.J.; Trojanowski, J.Q.; Wood, N.W.; Colosimo, C.; Dürr, A.; Fowler, C.J.; Kaufmann, H.; Klockgether, T.; Lees, A.; Poewe, W.; Quinn, N.; Revesz, T.; Robertson, D.; Sandroni, P.; Seppi, K.; Vidailhet, M. Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 2008, 71(9), 670-676.
[http://dx.doi.org/10.1212/01.wnl.0000324625.00404.15] [PMID: 18725592]
[15]
De Vincentis, G.; Frantellizzi, V.; Fedele, F.; Farcomeni, A.; Scarparo, P.; Salvi, N.; Fegatelli, D.A.; Mancone, M.; Verschure, D.O.; Verberne, H.J. Role of cardiac 123I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD. J. Nucl. Cardiol., 2019, 26(4), 1188-1196.
[PMID: 29594915]
[16]
Flotats, A.; Carrió, I.; Agostini, D.; Le Guludec, D.; Marcassa, C.; Schäfers, M.; Somsen, G.A.; Unlu, M.; Verberne, H.J. EANM cardiovascular committee; european council of nuclear cardiology. proposal for standardization of 123i-metaiodobenzylguanidine (mibg) cardiac sympathetic imaging by the EANM cardiovascular committee and the european council of nuclear cardiology. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(9), 1802-1812.
[http://dx.doi.org/10.1007/s00259-010-1491-4] [PMID: 20577740]
[17]
Generalised linear mixed models. Applied Mixed Models in Med 2014.
[18]
Verschure, D.O.; Poel, E.; Nakajima, K.; Okuda, K.; van Eck-Smit, B.L.F.; Somsen, G.A.; Verberne, H.J. A European myocardial 123I-mIBG cross-calibration phantom study. J. Nucl. Cardiol., 2018, 25(4), 1191-1197.
[http://dx.doi.org/10.1007/s12350-017-0782-6] [PMID: 28120154]
[19]
Zan, Y.; Long, Y.; Chen, K.; Li, B.; Huang, Q.; Gullberg, G.T. Design of a short nonuniform acquisition protocol for quantitative analysis in dynamic cardiac SPECT imaging - a retrospective 123 I-MIBG animal study. Med. Phys., 2017, 44(7), 3639-3649.
[http://dx.doi.org/10.1002/mp.12288] [PMID: 28429371]
[20]
Arimoto, T.; Takeishi, Y.; Fukui, A.; Tachibana, H.; Nozaki, N.; Hirono, O.; Yamaguchi, H.; Itoh, M.; Miyamoto, T.; Takahashi, H.; Okada, A.; Takahashi, K.; Kubota, I. Dynamic 123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. Ann. Nucl. Med., 2004, 18(2), 145-150.
[http://dx.doi.org/10.1007/BF02985105] [PMID: 15195762]
[21]
Ceccacci, A.; Mancone, M.; Calcagno, S.; De Vincentis, G.; Sardella, G.; Fedele, F. Role of MIBG scintigraphy in reverse Tako-tsubo cardiomyopathy: Confirming a pathophysiologic hypothesis. Int. J. Cardiol., 2016, 223, 54-55.
[http://dx.doi.org/10.1016/j.ijcard.2016.08.190] [PMID: 27529592]
[22]
Kinbara, T.; Hayano, T.; Otani, N.; Furutani, Y.; Tanaka, S. Iodine-123 metaiodobenzylguanidine imaging can predict future cardiac events in Japanese patients with parkinson’s disease. Ann. Nucl. Med., 2013, 27(2), 123-131.
[http://dx.doi.org/10.1007/s12149-012-0662-8] [PMID: 23086545]
[23]
Strano, S.; Fanciulli, A.; Rizzo, M.; Marinelli, P.; Palange, P.; Tiple, D.; De Vincentis, G.; Calcagnini, G.; Censi, F.; Meco, G.; Colosimo, C. Cardiovascular dysfunction in untreated parkinson’s disease: A multi-modality assessment. J. Neurol. Sci., 2016, 370, 251-255.
[http://dx.doi.org/10.1016/j.jns.2016.09.036] [PMID: 27772769]
[24]
Imamura, Y.; Ando, H.; Mitsuoka, W.; Egashira, S.; Masaki, H.; Ashihara, T.; Fukuyama, T. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J. Am. Coll. Cardiol., 1995, 26(7), 1594-1599.
[http://dx.doi.org/10.1016/0735-1097(95)00374-6] [PMID: 7594091]
[25]
Degrado, T.R.; Zalutsky, M.R.; Vaidyanathan, G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl. Med. Biol., 1995, 22(1), 1-12.
[http://dx.doi.org/10.1016/0969-8051(94)00084-W] [PMID: 7735158]
[26]
Uchiyama, Y.; Momose, M.; Kondo, C.; Kusakabe, K.; Uchiyama, S. Comparison of parameters of (123)I-metaiodobenzylguanidine scintigraphy for differential diagnosis in patients with parkinsonism: correlation with clinical features. Ann. Nucl. Med., 2011, 25(7), 478-485.
[http://dx.doi.org/10.1007/s12149-011-0490-2] [PMID: 21499991]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2020
Published on: 03 August, 2020
Page: [120 - 129]
Pages: 10
DOI: 10.2174/1874471013666200127122033
Price: $65

Article Metrics

PDF: 12
HTML: 1